
Datasheet

Version: 3.0.0 Revision date: 20 Aug 2025



MAP3K7IP1-S423 Antibody

Catalogue No.:abx033028



MAP3K7IP1 was identified as a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. This protein interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of this protein is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. This protein can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli.

Target: MAP3K7IP1-S423

Clonality: Polyclonal

Reactivity: Human

Tested Applications: ELISA, WB

Host: Rabbit

Recommended dilutions: WB: 1/1000. Optimal dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Immunogen: KLH-conjugated synthetic peptide between 401-430 amino acids from human MAP3K7IP1.

Isotype: IgG

Form: Liquid

Purification: Purified through a protein A column, followed by peptide affinity purification.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

UniProt Primary AC: Q15750 (UniProt, ExPASy)

Datasheet

Version: 3.0.0 Revision date: 20 Aug 2025



KEGG: hsa:10454

String: <u>9606.ENSP00000216160</u>

Molecular Weight: Calculated MW: 54.6 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC.

THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL

CONSUMPTION.